Commerce Bank Buys Shares of 17,206 Halozyme Therapeutics, Inc. $HALO

Key Points

• Commerce Bank initiated a $1.35 million position in Halozyme Therapeutics by purchasing 17,206 shares during the second quarter. Institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 beating estimates by $0.49 and revenue rising 47.7% year over year to $481 million. The stock opened at $109.32, near its 12-month high of $109.55.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $91.20, although recent targets range as high as $115. Insiders sold 64,103 shares worth approximately $5.23 million in the last quarter.

Commerce Bank bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,206 shares of the biopharmaceutical company's stock, valued at approximately $1,347,000.

Other large investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $59,000. Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $30,000. Evolve Private Wealth LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $253,000. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $196,540,000. Finally, EP Wealth Advisors LLC bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $686,000. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the company's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company's stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 64,103 shares of company stock worth $5,226,496. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Up 0.6%

Shares of NASDAQ:HALO opened at $109.32 on Wednesday. The stock has a 50 day moving average of $84.73 and a 200 day moving average of $74.19. The company has a market cap of $12.41 billion, a PE ratio of 32.63, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.55. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm's revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on HALO. UBS Group reiterated a "buy" rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. HC Wainwright upped their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Finally, Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source